N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-methanesulfonamide
• 英文别名: N-(2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)methanesulfonamide
• 化学式: C₁₆H₁₅N₃O₃S
• 分子量: 329.379
• InChiKey: ALMRWFJINQNLQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  96
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Benzodiazepine derivatives and pharmaceutical compositions containing them
  申请人：Carter Malcolm

  公开号：US20060040923A1

  公开（公告）日：2006-02-23

  Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: —R 1 represents C 1-6 alkyl, aryl or heteroaryl; —R 2 represents hydrogen or C 1-6 alkyl; —each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano, —CO 2 R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; —n is from 0 to 3; R 4 represents hydrogen or C 1-6 alkyl; —R 6 represents C 1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR 6 ; —X represents —CO—, —S(O)— or —S(O) 2 —; and —R 6 represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-(C 1-6 hydroxyalkyl)-, heteroaryl-(C 1-6 hydroxyalkyl)-, carbocyclyl-(C 1-6 hydroxyalkyl)-, heterocyclyl-(C 1-6 hydroxyalkyl)-, aryl-(C 1-6 alkyl)-O—, heteroaryl-(C 1-6 alkyl)-O—, carbocyclyl-(C 1-6 alkyl)-O—, heterocyclyl-(C 1-6 alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)- or heterocyclyl-(C 1-6 alkyl)-.

  公式（I）的苯二氮平衍生物及其药学上可接受的盐被发现对RSV具有活性。公式（I）中：-R1表示C1-6烷基，芳基或杂环芳基；-R2表示氢或C1-6烷基；-每个R3相同或不同，表示卤素，羟基，C1-6烷基，C1-6烷氧基，C1-6烷硫基，C1-6卤代烷基，C1-6卤代烷氧基，氨基，单（C1-6烷基）氨基，双（C1-6烷基）氨基，硝基，氰基，-CO2R'，-CONR'R"，-NH-CO-R'，-S（O）R'，-S（O）2R'，-NH-S（O）2R'，-S（O）NR'R"或-S（O）2NR'R"，其中每个R'和R"相同或不同，表示氢或C1-6烷基；-n为0-3；-R4表示氢或C1-6烷基；-R6表示C1-6烷基，芳基，杂环芳基，碳环基，杂环基，芳基（C1-6烷基），杂环芳基（C1-6烷基），碳环基（C1-6烷基），杂环基（C1-6烷基），芳基-C（O）-C（O）-，杂环芳基-C（O）-C（O）-，碳环基-C（O）-C（O）-，杂环基-C（O）-C（O）-或-XR6；-X表示-CO-，-S（O）-或-S（O）2-；-R6表示C1-6烷基，羟基，C1-6烷氧基，C1-6烷硫基，芳基，杂环芳基，碳环基，杂环基，芳基（C1-6烷氧基），杂环芳基（C1-6烷氧基），碳环基（C1-6烷氧基），杂环基（C1-6烷氧基），芳基（C1-6羟基烷基），杂环芳基（C1-6羟基烷基），碳环基（C1-6羟基烷基），杂环基（C1-6羟基烷基），芳基（C1-6烷基）-O-，杂环芳基（C1-6烷基）-O-，碳环基（C1-6烷基）-O-，杂环基（C1-6烷基）-O-或-NR'R"，其中每个R'和R"相同或不同，表示氢，C1-6烷基，碳环基，杂环基，芳基，杂环芳基，芳基（C1-6烷基），杂环芳基（C1-6烷基），碳环基（C1-6烷基）或杂环基（C1-6烷基）。
• Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them
  申请人：Carter Malcolm

  公开号：US20100015063A1

  公开（公告）日：2010-01-21

  Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV Formula (I) Wherein: —R 1 represents C 1-6 alkyl, aryl or heteroaryl; —R 2 represents hydrogen or C 1-6 alkyl; -each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano, —CO 2 R′, CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; -n is from 0 to 3; R 4 represents hydrogen or C 1-6 alkyl; —R 6 represents C 1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR 6 ; —X represents —CO—, —S(O)— or —S(0) 2 —; and —R 6 represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-(C 1-6 hydroxyalkyl)-, heteroaryl-(C 1-6 hydroxyalkyl)-, carbocyclyl-(C 1-6 hydroxyalkyl)-, heterocyclyl-(C 1-6 hydroxyalkyl)-, aryl-(C 1-6 alkyl)-O—, heteroaryl-(C 1-6 alkyl)-O—, carbocyclyl-(C 1-6 alkyl)-O—, heterocyclyl-(C 1-6 alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)- or heterocyclyl-(C 1-6 alkyl)-.

  公式（I）的苯二氮平衍生物及其药学上可接受的盐被发现对RSV具有活性，其中： - —R1代表C1-6烷基，芳基或杂环芳基； - —R2代表氢或C1-6烷基； - 每个R3相同或不同，代表卤素，羟基，C1-6烷基，C1-6烷氧基，C1-6烷基硫基，C1-6卤代烷基，C1-6卤代烷氧基，氨基，单（C1-6烷基）氨基，二（C1-6烷基）氨基，硝基，氰基，—CO2R′，CONR′R″，—NH—CO—R′，—S（O）R′，—S（O）2R′，—NH—S（O）2R′，—S（O）NR′R″或—S（O）2NR′R″，其中每个R′和R″相同或不同，代表氢或C1-6烷基； - n为0至3； - R4代表氢或C1-6烷基； - —R6代表C1-6烷基，芳基，杂环芳基，碳环烷基，杂环烷基，芳基-(C1-6烷基)-，杂环芳基-(C1-6烷基)-，碳环烷基-(C1-6烷基)-，杂环烷基-(C1-6烷基)-，芳基-C（O）-C（O）-，杂环芳基-C（O）-C（O）-，碳环烷基-C（O）-C（O）-，杂环烷基-C（O）-C（O）-或—XR6; - —X代表-CO-，-S（O）-或-S（0）2-； - —R6代表C1-6烷基，羟基，C1-6烷氧基，C1-6烷基硫基，芳基，杂环芳基，碳环烷基，杂环烷基，芳基-(C1-6烷基)-，杂环芳基-(C1-6烷基)-，碳环烷基-(C1-6烷基)-，杂环烷基-(C1-6烷基)-，芳基-(C1-6羟基烷基)-，杂环芳基-(C1-6羟基烷基)-，碳环烷基-(C1-6羟基烷基)-，杂环烷基-(C1-6羟基烷基)-，芳基-(C1-6烷基)-O-，杂环芳基-(C1-6烷基)-O-，碳环烷基-(C1-6烷基)-O-，杂环烷基-(C1-6烷基)-O-或—NR′R″，其中每个R′和R″相同或不同，代表氢，C1-6烷基，碳环烷基，杂环烷基，芳基，杂环芳基，芳基-(C1-6烷基)-，杂环芳基-(C1-6烷基)-，碳环烷基-(C1-6烷基)-或杂环烷基-(C1-6烷基)-。
• PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN
  申请人：Arrow Therapeutics Limited

  公开号：EP1727550B1

  公开（公告）日：2009-07-29
• Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
  申请人：Powell Kenneth

  公开号：US20070142403A1

  公开（公告）日：2007-06-21

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
• Process for Preparing Benzodiazepines
  申请人：Dowdell Verity

  公开号：US20070293482A1

  公开（公告）日：2007-12-20

  A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R 1 represents C 1-6 alkyl, aryl or heteroaryl; each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano, —CO 2 R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″, wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; n is from 0 to 3; X represents —NH—, —N(C 1 -C 6 alkyl)-, —CO—, —CO—NR′—, —S(O)— or —S(O) 2 —, wherein R′ is hydrogen or a C 1 -C 6 alkyl group; and R 4 represents hydrogen; or —CO—R 4 ′ or —CO—NH—R 4 ′ , wherein R 4 ′ is a C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C 1 -C 6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a —(C 1 -C 4 alkyl)-X 1 —(C 1 -C 4 alkyl)-X 2 —(C 1 -C 4 alkyl) group, wherein X 1 represents —O—, —S— or —NR′—, wherein R′ represents H or a C 1 -C 4 alkyl group and X 2 represents —CO—, —SO— or —SO 2 —; or R 4 ′ represents -A 1 -Y-A 2 , wherein: A 1 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; Y represents a direct bond or a C 1 -C 4 alkylene, —SO 2 —, —CO—, —O—, —S or —NR′—, wherein R′ is a C 1 -C 6 alkyl group; and A 2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; or R 4 is a group selected from aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— and -ZR 5 , wherein: Z represents —CO—, —S(O)— or —S(O) 2 ′; and R 5 represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-(C 1-6 alkyl)-O—, heteroaryl-(C 1-6 alkyl)-O—, carbocyclyl-(C 1-6 alkyl)-O—, heterocyclyl-(C 1-6 alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)- or heterocyclyl-(C 1-6 alkyl)-; or a pharmaceutically acceptable salt thereof; which process comprises: (a) subjecting a racemic benzodiazepine derivative of formula: (IIa): wherein R 1 , R 3 , R 4 , n and X are as defined above, and R 2 represents an amino protecting group, to crystallisation induced dynamic resolution to yield a benzodiazepine derivative of formula (II): wherein, R 1 , R 2 , R 3 , R 4 , n and X are as defined above; and (b) deprotecting the benzodiazepine derivative of formula (II) as defined above to yield a benzodiazepine derivative of formula (I) or a pharmaceutically acceptable form thereof as defined above.